Mechanisms · Mechanism of Action
Mu-Opioid Receptor
Ibogaine and noribogaine interact with the mu-opioid receptor at low affinity — but the clinical effect on opioid withdrawal is multifactorial, not a simple substitute-and-taper.
Quick Answer
What is mu-opioid receptor in ibogaine pharmacology?
Reviewed by Dr. Arellano, M.D. — May 2026
Binding profile at the mu-opioid receptor
Ibogaine binds the mu-opioid receptor at micromolar affinity — orders of magnitude weaker than morphine or fentanyl. Functional assays vary in whether they classify ibogaine as a partial agonist, antagonist, or biased ligand.
Noribogaine, the in vivo O-demethylated metabolite, has cleaner partial-agonist activity at mu and kappa-opioid receptors. Its long plasma half-life means noribogaine carries much of the post-flood-dose opioid-receptor activity.
Why low affinity still interrupts withdrawal
Withdrawal interruption in opioid use disorder is observed within hours of the flood dose — a kinetic that pure mu-receptor occupancy cannot explain.
Current models attribute the rapid withdrawal interruption to: (1) noribogaine's sustained mu/kappa partial-agonist activity, (2) NMDA-receptor antagonism resetting opioid-tolerance pathways, (3) GDNF-mediated dopaminergic repair, and (4) sigma-2 receptor activity affecting reward-circuit signaling.
Clinical signal in the literature
Mash et al. (2018) and Brown & Alper (2018) report sustained reductions in opioid use and withdrawal symptoms in carefully screened cohorts. Knuijver et al. (2022) provide controlled detoxification data with monitored cardiac safety.
These are open-label observational studies, not double-blind randomized controlled trials. The signal is consistent across cohorts, but the field still needs RCT-grade evidence — which is what the ongoing 2026 trials at Stanford and Ambio aim to provide.
Targets
- Mu-opioid receptor (MOR)
- Kappa-opioid receptor (KOR)
- Noribogaine
Citations & Reading
- Mash DC, et al. (2018). Frontiers in Pharmacology, 9, 529.
- Brown TK, Alper K. (2018). The American Journal of Drug and Alcohol Abuse, 44(1), 24-36.
- Knuijver T, et al. (2022). Addiction, 117(1), 118-128.
- Cherian KN, et al. (2024). Nature Medicine, 30, 373-381.
- Maillet EL, et al. (2015). Neuropharmacology, 99, 675-688.
For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.
Related mechanisms
NMDA Receptor Antagonism
Ibogaine is a non-competitive NMDA receptor antagonist — a mechanism it shares with ketamine, dextromethorphan, and memantine, with implications for tolerance reversal and dissociative experience.
Noribogaine — The Long-Tail Metabolite
Noribogaine is ibogaine's CYP2D6-formed metabolite — cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.
BDNF & GDNF Upregulation
Ibogaine and noribogaine upregulate brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), driving downstream neuroplasticity and dopaminergic repair.
Ibogaine Pharmacokinetics
Absorption, CYP2D6 metabolism to noribogaine, distribution, and elimination — including the long noribogaine tail that drives the post-flood telemetry window.